

David Webb

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7542302/david-webb-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126
papers

9,030
citations

44
h-index

94
g-index

138
ext. papers

10,306
ext. citations

8.4
avg, IF

5.93
L-index

#	Paper	IF	Citations
126	Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial.. <i>Circulation</i> , 2022 , 145, 416-423	16.7	1
125	Budget impact analysis of a pilot polypharmacy clinic. <i>British Journal of Health Care Management</i> , 2022 , 28, 1-9	0.4	
124	Serial troponin measurements to monitor risk and response to endothelin A antagonism in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 375-377	4.3	0
123	Sodium-Glucose Co-Transporter \geq Inhibitors (SGLT2i) Exposure and Outcomes in Type \geq Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021 , 12, 991-1028	3.6	8
122	Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021 , 30, 456-465	3.5	1
121	Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD). <i>American Journal of Hypertension</i> , 2021 , 34, 92-99	2.3	2
120	Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease. <i>iScience</i> , 2021 , 24, 101937	6.1	3
119	Glucagon-Like Peptide \geq Receptor Agonist (GLP1RA) Exposure and Outcomes in Type \geq Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021 , 12, 969-989	3.6	1
118	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy for Glycemic Management in Monotherapy in Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 2001-2011	14.6	5
117	The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. <i>Kidney International</i> , 2020 , 98, 323-342	9.9	22
116	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020 , 177, 5467-5488	8.6	34
115	Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated kidney, eye and vessel injury. <i>Kidney International</i> , 2020 , 98, 1193-1209	9.9	4
114	Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development. <i>Cell Stem Cell</i> , 2020 , 27, 822-839.e8	18	17
113	Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , 2020 , 41, 1606-1607	9.5	11
112	Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1907-1924	3.8	6
111	Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose. <i>EClinicalMedicine</i> , 2019 , 11, 11-17	11.3	24
110	Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2019 , 74, 323-330	8.5	11

109	Retinal fingerprints for precision profiling of cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2019 , 16, 379-381	14.8	4
108	Endothelins in cardiovascular biology and therapeutics. <i>Nature Reviews Cardiology</i> , 2019 , 16, 491-502	14.8	98
107	Improving medication safety: focus on prescribers and systems. <i>Lancet, The</i> , 2019 , 394, 283-285	40	10
106	Endothelin signalling mediates experience-dependent myelination in the CNS. <i>ELife</i> , 2019 , 8,	8.9	36
105	A novel role for myeloid endothelin-B receptors in hypertension. <i>European Heart Journal</i> , 2019 , 40, 768-784	9.9	18
104	Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 464-475	18.1	126
103	Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney disease. <i>Kidney International</i> , 2018 , 93, 270	9.9	3
102	Long-term adverse effects of paracetamol - a review. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2218-2230	3.8	69
101	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 451-454	1.9	14
100	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 462-471	1.9	8
99	First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis. <i>Hypertension</i> , 2017 , 70, 192-200	8.5	6
98	Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7343 UK final-year medical students. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2249-2258	3.8	34
97	Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes. <i>Diabetologia</i> , 2017 , 60, 1400-1408	10.3	8
96	Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling. <i>Hypertension</i> , 2017 , 69, 275-285	8.5	10
95	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017 , 17, 441-448	3.4	6
94	Characterization of Triptolide-Induced Hepatotoxicity by Imaging and Transcriptomics in a Novel Zebrafish Model. <i>Toxicological Sciences</i> , 2017 , 159, 380-391	4.4	14
93	A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2339-2342	3.8	1
92	Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	57

91	Ethanol consumption produces a small increase in circulating miR-122 in healthy individuals. <i>Clinical Toxicology</i> , 2016 , 54, 53-5	2.9	25
90	Endothelin. <i>Pharmacological Reviews</i> , 2016 , 68, 357-418	22.5	400
89	Therapeutic potential of endothelin receptor antagonism in kidney disease. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016 , 310, R388-97	3.2	17
88	Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 136-47	18.1	72
87	Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. <i>JCI Insight</i> , 2016 , 1, e89173	9.9	37
86	Arterial stiffness & Sri Lankan chronic kidney disease of unknown origin. <i>Scientific Reports</i> , 2016 , 6, 32599	4.9	6
85	Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. <i>BMJ Open</i> , 2016 , 6, e010313	3	39
84	Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes. <i>Kidney International</i> , 2016 , 89, 1125-1135	9.9	45
83	New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension. <i>Current Hypertension Reports</i> , 2016 , 18, 34	4.7	22
82	Endothelin in nondiabetic chronic kidney disease: preclinical and clinical studies. <i>Seminars in Nephrology</i> , 2015 , 35, 176-87	4.8	11
81	Imaging of cardiovascular risk in patients with Turner's syndrome. <i>Clinical Radiology</i> , 2015 , 70, 803-14	2.9	21
80	Sildenafil improves renal function in patients with pulmonary arterial hypertension. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 235-41	3.8	13
79	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. <i>BMJ Open</i> , 2015 , 5, e008951	3	12
78	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet, The</i> , 2015 , 386, 2059-2068	4.0	632
77	Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial. <i>BMJ Open</i> , 2015 , 5, e007645	3	8
76	Generation and 3-Dimensional Quantitation of Arterial Lesions in Mice Using Optical Projection Tomography. <i>Journal of Visualized Experiments</i> , 2015 , e50627	1.6	3
75	Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism. <i>Journal of the American Heart Association</i> , 2015 , 4, e001624 ⁶		11
74	Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. <i>BMJ Open</i> , 2015 , 5, e008086	3	5

73	Prescribing safety: ensuring that new graduates are prepared. <i>Lancet, The</i> , 2015 , 385, 579-581	40	27
72	Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease. <i>Journal of Lipid Research</i> , 2015 , 56, 413-22	6.3	54
71	Aortic dissection in children and adolescents with Turner syndrome: risk factors and management recommendations. <i>Archives of Disease in Childhood</i> , 2015 , 100, 662-6	2.2	24
70	Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 636-646	15.1	1076
69	Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 521-7	5.8	28
68	Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. <i>Lancet, The</i> , 2014 , 383, 697-704	40	129
67	Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1050-62	12.7	67
66	Prevalence and causes of prescribing errors: the PRescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) study. <i>PLoS ONE</i> , 2014 , 9, e79802	3.7	103
65	A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 1396-405	3.8	19
64	Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 31-6	12.7	31
63	Value-based medicine pricing: NICE work?. <i>Lancet, The</i> , 2011 , 377, 1552-3	40	13
62	Circulating microRNAs as potential markers of human drug-induced liver injury. <i>Hepatology</i> , 2011 , 54, 1767-76	11.2	403
61	11 β hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe ^{-/-} mice. <i>Endocrinology</i> , 2011 , 152, 236-246	4.8	70
60	Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. <i>Hypertension</i> , 2011 , 57, 772-9	8.5	111
59	Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. <i>Hypertension</i> , 2010 , 55, 1406-11	8.5	11
58	Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. <i>Hypertension</i> , 2009 , 54, 113-9	8.5	94
57	Reply to J Rood and SR Smith. <i>American Journal of Clinical Nutrition</i> , 2008 , 88, 249-250	7	3
56	Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 3228-34	4.3	41

55	The endothelin system and its antagonism in chronic kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 943-55	12.7	184
54	Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. <i>British Journal of Cancer</i> , 2005 , 92, 2148-52	8.7	75
53	A Comparison of the Haemodynamic Effects Pentaerythritol Tetranitrate and Isosorbide Mononitrate in Healthy Men. <i>Clinical Science</i> , 2003 , 104, 16P-16P		
52	ACE inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 337-337	3.8	78
51	Differential vasoactive response to endothelin receptor antagonists and prostacyclin in patients with severe pulmonary hypertension. <i>Clinical Science</i> , 2002 , 103 Suppl 48, 298S-301S	6.5	3
50	Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 631-46	3.8	228
49	Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 159-64	3.8	46
48	Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. <i>Hepatology</i> , 2001 , 33, 826-31	11.2	34
47	Gastrin-releasing peptide is a potent vasodilator in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 252-9	6.1	14
46	Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. <i>British Journal of Pharmacology</i> , 2001 , 134, 648-54	8.6	65
45	Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. <i>Journal of Physiology</i> , 2001 , 530, 541-50	3.9	128
44	Short-term effects of transdermal nicotine on acute tissue plasminogen activator release in vivo in man. <i>Cardiovascular Research</i> , 2001 , 52, 321-7	9.9	19
43	Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 295-301	4.3	7
42	Venous endothelin receptor function in patients with chronic heart failure. <i>Clinical Science</i> , 2000 , 98, 65-70	6.5	14
41	Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin s6c, in human resistance and capacitance vessels in vivo. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 27-30	3.8	10
40	Research methods in human cardiovascular pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 395	3.8	1
39	Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contraction. <i>British Journal of Pharmacology</i> , 2000 , 130, 1735-44	8.6	13
38	S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. <i>British Journal of Pharmacology</i> , 2000 , 131, 1236-44	8.6	44

37	Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. <i>British Journal of Pharmacology</i> , 2000 , 131, 1391-8	8.6	24
36	The influence of heart rate on augmentation index and central arterial pressure in humans. <i>Journal of Physiology</i> , 2000 , 525 Pt 1, 263-70	3.9	75 ⁸
35	A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 75-81	6.1	12
34	Big endothelin-3 constricts forearm resistance vessels but not hand veins in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 67-74	6.1	1
33	Acute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty. <i>Circulation</i> , 2000 , 102, 1937-43	16.7	24
32	Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 336-44	3.8	22
31	Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. <i>British Journal of Clinical Pharmacology</i> , 1999 , 47, 507-13	3.8	20
30	Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders. <i>Drugs in R and D</i> , 1999 , 2, 1-12	3.4	7
29	Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. <i>British Journal of Clinical Pharmacology</i> , 1998 , 45, 545-50	3.8	116
28	Clinical experience with endothelin antagonists. <i>American Journal of Hypertension</i> , 1998 , 11, 715-79S	2.3	21
27	Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study. <i>BMJ: British Medical Journal</i> , 1998 , 316, 834-7		74
26	Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. <i>Circulation</i> , 1998 , 97, 2323-30	16.7	142
25	The endothelin system: a novel therapeutic target in cardiovascular disease. <i>Expert Opinion on Emerging Drugs</i> , 1998 , 3, 95-112		3
24	Seasonal variation in glucocorticoid activity in healthy men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 4015-9	5.6	120
23	Endothelial dysfunction and hypertension. <i>Drugs</i> , 1997 , 53 Suppl 1, 30-41	12.1	39
22	Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. <i>British Journal of Pharmacology</i> , 1997 , 120, 1376-82	8.6	81
21	Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. <i>British Journal of Clinical Pharmacology</i> , 1997 , 43, 493-9	3.8	32
20	Endothelin: from molecule to man. <i>British Journal of Clinical Pharmacology</i> , 1997 , 44, 9-20	3.8	46

19	The clinical section of the British Pharmacological Society: prospects for the future. <i>British Journal of Clinical Pharmacology</i> , 1997 , 44, 215-8	3.8	
18	Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 327-33	6.1	3
17	An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 1242-1248	7	67
16	The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. <i>British Journal of Pharmacology</i> , 1996 , 119, 311-4	8.6	53
15	The clinical potential of endothelin receptor antagonists in cardiovascular medicine. <i>Drugs</i> , 1996 , 51, 12-27	12.1	58
14	The endothelin system and its potential as a therapeutic target in cardiovascular disease 1996 , 72, 109-48		136
13	Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. <i>Circulation</i> , 1996 , 93, 1860-70	16.7	212
12	Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. <i>Circulation</i> , 1996 , 93, 1331-3	16.7	193
11	Endothelin and blood pressure regulation. <i>Journal of Human Hypertension</i> , 1996 , 10, 383-6	2.6	1
10	Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. <i>British Journal of Pharmacology</i> , 1995 , 116, 1821-8	8.6	38
9	The role of endothelin-1 in cardiovascular physiology and pathophysiology. <i>Scottish Medical Journal</i> , 1995 , 40, 69-71	1.8	4
8	Endogenous endothelin generation maintains vascular tone in humans. <i>Journal of Human Hypertension</i> , 1995 , 9, 459-63	2.6	10
7	Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. <i>Circulation</i> , 1995 , 92, 357-63	16.7	194
6	Measuring forearm blood flow and interpreting the responses to drugs and mediators. <i>Hypertension</i> , 1995 , 25, 918-23	8.5	235
5	Contribution of endogenous generation of endothelin-1 to basal vascular tone. <i>Lancet, The</i> , 1994 , 344, 852-4	40	517
4	Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. <i>British Journal of Clinical Pharmacology</i> , 1993 , 36, 293-301	3.8	3
3	Endothelins come of age. <i>Lancet, The</i> , 1993 , 342, 1439-40	40	19
2	Endothelium-dependent modulation of responses to endothelin-I in human veins. <i>Clinical Science</i> , 1993 , 84, 427-33	6.5	55

1	Ultraviolet A Radiation and COVID-19 Deaths in the USA with replication studies in England and Italy	3
---	--	---